Palbociclib + Ganitumab In Ewing Sarcoma

NCT04129151 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped The study closed early due to discontinuation of ganitumab supply.

Conditions

Ewing Sarcoma
Ewing's Sarcoma Recurrent

Interventions

DRUG: Palbociclib
DRUG: Ganitumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]